MCID: HDG005
MIFTS: 30

Hodgkin's Lymphoma, Mixed Cellularity

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Hodgkin's Lymphoma, Mixed Cellularity

MalaCards integrated aliases for Hodgkin's Lymphoma, Mixed Cellularity:

Name: Hodgkin's Lymphoma, Mixed Cellularity 12 15
Hodgkin's Disease, Mixed Cellularity of Unspecified Site 12
Hodgkin's Disease, Mixed Cellularity 12
Hodgkin Lymphoma, Mixed Cellularity 12
Mixed Cellularity Hodgkin Lymphoma 73
Mchl 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8654
ICD10 33 C81.2
ICD9CM 35 201.6
MeSH 44 D006689
NCIt 50 C3517
UMLS 73 C0152266

Summaries for Hodgkin's Lymphoma, Mixed Cellularity

MalaCards based summary : Hodgkin's Lymphoma, Mixed Cellularity, also known as hodgkin's disease, mixed cellularity of unspecified site, is related to classic hodgkin lymphoma, mixed cellularity type and lymphoma, hodgkin, classic, and has symptoms including fever and night sweats. An important gene associated with Hodgkin's Lymphoma, Mixed Cellularity is PHYH (Phytanoyl-CoA 2-Hydroxylase), and among its related pathways/superpathways is Peroxisome. The drugs Lenograstim and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow.

Related Diseases for Hodgkin's Lymphoma, Mixed Cellularity

Graphical network of the top 20 diseases related to Hodgkin's Lymphoma, Mixed Cellularity:



Diseases related to Hodgkin's Lymphoma, Mixed Cellularity

Symptoms & Phenotypes for Hodgkin's Lymphoma, Mixed Cellularity

UMLS symptoms related to Hodgkin's Lymphoma, Mixed Cellularity:


fever, night sweats

Drugs & Therapeutics for Hodgkin's Lymphoma, Mixed Cellularity

Drugs for Hodgkin's Lymphoma, Mixed Cellularity (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 110)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
2
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
3
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
4
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
5
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
6
Vinblastine Approved Phase 3,Phase 2 865-21-4 13342 241903
7
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
8
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
9
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
10
Bleomycin Approved, Investigational Phase 3,Phase 2 11056-06-7 5360373
11
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
12
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
13
Cortisone acetate Approved, Investigational Phase 3 1950-04-4, 50-04-4 5745
14
Procarbazine Approved, Investigational Phase 3,Phase 2 671-16-9 4915
15
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
16
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
17
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
18
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 60780 44424639
19
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
20
Doxil Approved June 1999 Phase 3,Phase 2 31703
21
Imidazole Experimental, Investigational Phase 3,Phase 2 288-32-4 795
22 Alkylating Agents Phase 3,Phase 2,Phase 1
23 glucocorticoids Phase 3,Phase 2
24 Adjuvants, Immunologic Phase 3,Phase 2
25 Topoisomerase Inhibitors Phase 3,Phase 2
26 Hormone Antagonists Phase 3,Phase 2
27 Hormones Phase 3,Phase 2
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
29 Anti-Bacterial Agents Phase 3,Phase 2
30 Antibiotics, Antitubercular Phase 3,Phase 2
31 Etoposide phosphate Phase 3,Phase 2
32 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
33 Anti-Inflammatory Agents Phase 3,Phase 2
34 Antirheumatic Agents Phase 3,Phase 2
35 Antimitotic Agents Phase 3,Phase 2
36 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
37 Antineoplastic Agents, Hormonal Phase 3,Phase 2
38 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
39 Podophyllotoxin Phase 3,Phase 2 518-28-5
40 Prednisolone acetate Phase 3,Phase 2
41
Cortisone Phase 3 53-06-5 222786
42 Dexamethasone acetate Phase 3 1177-87-3
43
Isophosphamide mustard Phase 3,Phase 2 0
44
protease inhibitors Phase 3
45 Methylprednisolone acetate Phase 3,Phase 2
46 Methylprednisolone Hemisuccinate Phase 3,Phase 2
47 Fluorodeoxyglucose F18 Phase 3,Phase 2
48 Gastrointestinal Agents Phase 3,Phase 2
49 Neuroprotective Agents Phase 3,Phase 2
50 HIV Protease Inhibitors Phase 3

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma Unknown status NCT00041210 Phase 3 ABVD regimen;Stanford V regimen;dacarbazine;doxorubicin hydrochloride;etoposide;mechlorethamine hydrochloride;prednisone;vinblastine sulfate;vincristine sulfate
2 Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma Completed NCT00433433 Phase 3 ABVD q4 weeks;BEACOPP escalated q3 weeks
3 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed NCT00025259 Phase 3 Cisplatin;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate Liposome
4 Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease Completed NCT00002561 Phase 3 dacarbazine;doxorubicin hydrochloride;vinblastine
5 Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma Completed NCT00433459 Phase 3 cyclophosphamide;dacarbazine;prednisolone;prednisone;procarbazine hydrochloride;vincristine sulfate
6 Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Completed NCT00003389 Phase 3 Doxorubicin;Bleomycin;Vinblastine;Dacarbazine;Vincristine;Mechlorethamine;Etoposide;Prednisone;Cyclophosphamide
7 Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma Active, not recruiting NCT00302003 Phase 3 doxorubicin hydrochloride;vincristine sulfate;prednisone;cyclophosphamide;ifosfamide;vinorelbine tartrate;dexamethasone;etoposide phosphate;cisplatin;cytarabine
8 Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma Active, not recruiting NCT00049595 Phase 3 ABVD regimen;BEACOPP regimen;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
9 Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma Active, not recruiting NCT00678327 Phase 3 cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;prednisolone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
10 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00002461 Phase 2 carmustine;cisplatin;cyclophosphamide;etoposide
11 Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma Unknown status NCT00002715 Phase 2 Stanford V regimen;doxorubicin hydrochloride;etoposide;mechlorethamine hydrochloride;prednisone;vinblastine;vincristine sulfate
12 Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma Completed NCT00082966 Phase 2 17-N-allylamino-17-demethoxygeldanamycin/bortezomib
13 Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma Completed NCT00255723 Phase 2 carboplatin;etoposide;ifosfamide
14 SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Completed NCT00337194 Phase 2 vinorelbine tartrate;pegylated liposomal doxorubicin hydrochloride;gemcitabine hydrochloride
15 Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy Completed NCT00381940 Phase 2 ifosfamide;bortezomib;vinorelbine tartrate
16 A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma Completed NCT01460940 Phase 2 panobinostat;lenalidomide
17 Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma Completed NCT00070304 Phase 2 gemcitabine hydrochloride;vinorelbine tartrate
18 Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma Completed NCT00006760 Phase 2 ifosfamide;vinorelbine tartrate
19 Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma Completed NCT00132028 Phase 2 vorinostat
20 Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin's Lymphoma Completed NCT00369681 Phase 2 ABVD regimen;dacarbazine;doxorubicin;vinblastine
21 Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. Completed NCT01022996 Phase 2 Everolimus (RAD001)
22 Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma Completed NCT00666484 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisolone;procarbazine hydrochloride;vincristine sulfate
23 Combination Chemotherapy in Treating Young Male Patients With Hodgkin's Lymphoma Completed NCT00398554 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vinblastine sulfate;vincristine sulfate
24 Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease Completed NCT00004010 Phase 2 ABVD regimen;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
25 PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma Recruiting NCT03226249 Phase 2 Dacarbazine;Doxorubicin Hydrochloride;Vinblastine Sulfate
26 Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Recruiting NCT03077828 Phase 2 Carboplatin;Etoposide;Ifosfamide
27 Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma Active, not recruiting NCT01535924 Phase 1, Phase 2 gemcitabine hydrochloride;bendamustine hydrochloride
28 Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma Active, not recruiting NCT01476410 Phase 2 brentuximab vedotin;doxorubicin hydrochloride;vinblastine;dacarbazine
29 Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma Active, not recruiting NCT00574496 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;gemcitabine hydrochloride;ifosfamide;mechlorethamine hydrochloride;melphalan;methotrexate;mycophenolate mofetil;prednisone;procarbazine hydrochloride;vincristine sulfate;vinorelbine tartrate
30 S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Active, not recruiting NCT00822120 Phase 2 ABVD regimen;BEACOPP regimen;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
31 Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma Active, not recruiting NCT01118026 Phase 2 ABVD;BEACOPP
32 Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma Terminated NCT00112723 Phase 1, Phase 2 alvocidib
33 Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma Terminated NCT01390584 Phase 2 ABVD Induction;Escalated BEACOPP;Standard BEACOPP
34 Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment Withdrawn NCT00881387 Phase 2 gemcitabine hydrochloride;vinorelbine ditartrate
35 CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma Recruiting NCT02168140 Phase 1 6,8-bis(benzylthio)octanoic acid;bendamustine hydrochloride
36 Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma Completed NCT01490801
37 Protein Biomarker Levels in Tissue Samples From Young Patients With Low-risk Hodgkin Lymphoma Completed NCT01366157

Search NIH Clinical Center for Hodgkin's Lymphoma, Mixed Cellularity

Genetic Tests for Hodgkin's Lymphoma, Mixed Cellularity

Anatomical Context for Hodgkin's Lymphoma, Mixed Cellularity

MalaCards organs/tissues related to Hodgkin's Lymphoma, Mixed Cellularity:

41
T Cells, Bone, Bone Marrow

Publications for Hodgkin's Lymphoma, Mixed Cellularity

Articles related to Hodgkin's Lymphoma, Mixed Cellularity:

# Title Authors Year
1
Concurrent Hodgkin's disease (mixed cellularity type) and T-cell chronic lymphocytic leukemia/prolymphocytic leukemia. ( 11372737 )
2001

Variations for Hodgkin's Lymphoma, Mixed Cellularity

Expression for Hodgkin's Lymphoma, Mixed Cellularity

Search GEO for disease gene expression data for Hodgkin's Lymphoma, Mixed Cellularity.

Pathways for Hodgkin's Lymphoma, Mixed Cellularity

Pathways related to Hodgkin's Lymphoma, Mixed Cellularity according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.54 ACSL1 PHYH

GO Terms for Hodgkin's Lymphoma, Mixed Cellularity

Cellular components related to Hodgkin's Lymphoma, Mixed Cellularity according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peroxisome GO:0005777 8.62 ACSL1 PHYH

Molecular functions related to Hodgkin's Lymphoma, Mixed Cellularity according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ligase activity GO:0016874 8.62 ACSL1 UCHL1

Sources for Hodgkin's Lymphoma, Mixed Cellularity

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....